Abstract |
The lipid-lowering effects of 1-[2-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-1,2,3,5-tetrahydro-2-oxo-5-(2,3-dimethoxyphenyl)-4,1-benzoxazepine-3-yl] acetyl] piperidin-4-acetic acid (TAK-475), a novel squalene synthase inhibitor, were examined in two models of familial hypercholesterolemia, low-density lipoprotein ( LDL) receptor knockout mice and Watanabe heritable hyperlipidemic (WHHL) rabbits. Two weeks of treatment with TAK-475 in a diet admixture (0.02% and 0.07%; approximately 30 and 110 mg/kg/day, respectively) significantly lowered plasma non- high-density lipoprotein ( HDL) cholesterol levels by 19% and 41%, respectively, in homozygous LDL receptor knockout mice. The 3-hydroxy-3-methylglutaryl coenzyme A ( HMG-CoA) reductase inhibitors, simvastatin and atorvastatin (in 0.02% and 0.07% admixtures), also reduced plasma levels of non- HDL cholesterol. In homozygous WHHL rabbits, 4 weeks of treatment with TAK-475 (0.27%; approximately 100 mg/kg/day) lowered plasma total cholesterol, triglyceride and phospholipid levels by 17%, 52% and 26%, respectively. In Triton WR-1339-treated rabbits, TAK-475 inhibited to the same extent the rate of secretion from the liver of the cholesterol, triglyceride and phospholipid components of very-low-density lipoprotein (VLDL). These results suggest that the lipid-lowering effects of TAK-475 in WHHL rabbits are based partially on the inhibition of secretion of VLDL from the liver. TAK-475 had no effect on plasma aspartate aminotransferase and alanine aminotransferase activities. Thus, the squalene synthase inhibitor TAK-475 revealed lipid-lowering effects in both LDL receptor knockout mice and WHHL rabbits.
|
Authors | Yuichiro Amano, Tomoyuki Nishimoto, Ryu ichi Tozawa, Eiichiro Ishikawa, Yoshimi Imura, Yasuo Sugiyama |
Journal | European journal of pharmacology
(Eur J Pharmacol)
Vol. 466
Issue 1-2
Pg. 155-61
(Apr 11 2003)
ISSN: 0014-2999 [Print] Netherlands |
PMID | 12679152
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid
- Cholesterol, HDL
- Enzyme Inhibitors
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Oxazepines
- Piperidines
- Pyrroles
- Receptors, LDL
- Triglycerides
- Atorvastatin
- Simvastatin
- Farnesyl-Diphosphate Farnesyltransferase
|
Topics |
- Administration, Oral
- Animals
- Atorvastatin
- Cholesterol, HDL
(blood)
- Disease Models, Animal
- Enzyme Inhibitors
(pharmacology)
- Farnesyl-Diphosphate Farnesyltransferase
(antagonists & inhibitors)
- Female
- Heptanoic Acids
(pharmacology)
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(pharmacology)
- Hyperlipoproteinemia Type II
(drug therapy)
- Male
- Mice
- Mice, Knockout
- Oxazepines
(pharmacology)
- Piperidines
(pharmacology)
- Pyrroles
(pharmacology)
- Rabbits
- Receptors, LDL
(genetics)
- Simvastatin
(pharmacology)
- Species Specificity
- Time Factors
- Triglycerides
(blood)
|